Mesoblast has created a new Head of Clinical Development and Medical Affairs position and appointed Teresa Montagut MD, PhD to report to Chief Medical Officer Dr. Eric Rose. In this capacity, Montagut will oversee investigator-initiated trials, foster clinical collaborations and enhance medical communications to drive Ryoncil’s expansion into pediatric and adult inflammatory conditions.

Dr. Montagut joins Mesoblast from Regeneron, where she led early pipeline oncology studies and managed investigator-sponsored gastroenterology and genitourinary trials. Her career includes senior roles in immuno-oncology at Novartis, Genentech and Atara Biotherapeutics, where she advanced multiple cancer immunotherapy programs.

By strengthening its medical affairs leadership, Mesoblast aims to accelerate clinical development and broaden the indications of its FDA-approved Ryoncil cell therapy. Montagut’s expertise should enhance investigator partnerships and could improve trial design, potentially accelerating product uptake and supporting future filings for adult SR-aGvHD and biologic-resistant IBD.

Mesoblast’s portfolio includes Ryoncil for pediatric SR-aGvHD, remestemcel-L for adult inflammatory bowel disease and rexlemestrocel-L for heart failure and low back pain. The company holds over 1,000 patents with protection through 2044 and maintains partnerships across Japan, Europe and China to support global commercialization.